CNBX PHARMACEUTICALS INC. (CNBX) earnings per share
| Period | End | Diluted | Filed |
|---|---|---|---|
| FY 2025 | 2025-08-31 | $0.00 | 2025-12-01 |
| FY 2024 | 2024-08-31 | -$0.02 | 2024-11-29 |
| FY 2023 | 2023-08-31 | -$0.42 | 2023-11-30 |
| FY 2022 | 2022-08-31 | -$3.59 | 2022-11-30 |
| FY 2021 | 2021-08-31 | -$0.02 | 2021-11-29 |
| Period | End | Diluted | Filed |
|---|---|---|---|
| Q2 2026 | 2026-02-28 | $0.00 | 2026-04-14 |
| Q1 2026 | 2025-11-30 | $0.00 | 2026-01-14 |
| Q4 2025 | 2025-08-31 | $0.00 | 2025-12-01 |
| Q3 2025 | 2025-05-31 | $0.00 | 2025-07-14 |
| Q2 2025 | 2025-02-28 | $0.00 | 2025-04-14 |
| Q1 2025 | 2024-11-30 | -$0.00 | 2025-01-13 |
| Q4 2024 | 2024-08-31 | $0.00 | 2024-11-29 |
| Q3 2025 | 2024-05-31 | $0.00 | 2024-07-15 |
| Q2 2024 | 2024-02-29 | -$0.01 | 2024-04-16 |
| Q1 2024 | 2023-11-30 | -$0.01 | 2024-01-12 |
| Q4 2023 | 2023-08-31 | $0.36 | 2023-11-30 |
| Q3 2023 | 2023-05-31 | -$0.02 | 2023-07-14 |
| Q2 2023 | 2023-02-28 | -$1.33 | 2023-04-14 |
| Q1 2023 | 2022-11-30 | -$0.33 | 2023-01-13 |
| Q4 2022 | 2022-08-31 | -$0.94 | 2022-11-30 |
| Q3 2022 | 2022-05-31 | -$0.05 | 2022-07-14 |
| Q2 2022 | 2022-02-28 | -$1.01 | 2022-04-12 |
| Q1 2022 | 2021-11-30 | -$0.01 | 2022-01-13 |
| Q4 2021 | 2021-08-31 | $2.19 | 2021-11-29 |
| Q3 2021 | 2021-05-31 | -$1.17 | 2021-07-14 |
| Q2 2021 | 2021-02-28 | — | 2021-04-14 |
| Q3 2016 | 2016-05-31 | — | 2016-07-13 |
| Q2 2016 | 2016-02-29 | — | 2016-04-18 |
| Q1 2016 | 2015-11-30 | — | 2016-01-22 |
| Q3 2015 | 2015-05-31 | — | 2015-07-15 |
| Q2 2015 | 2015-02-28 | — | 2015-04-20 |
| Q1 2015 | 2014-11-30 | — | 2015-01-20 |
| Period | End | FCF / Share | Filed |
|---|---|---|---|
| Q3 2016 | 2016-05-31 | -$0.06 | 2016-07-13 |
| Q2 2016 | 2016-02-29 | -$0.07 | 2016-04-18 |
| Q1 2016 | 2015-11-30 | -$0.05 | 2016-01-22 |
| Q3 2015 | 2015-05-31 | -$0.18 | 2015-07-15 |
| Q2 2015 | 2015-02-28 | -$0.20 | 2015-04-20 |
| Q1 2015 | 2014-11-30 | -$0.13 | 2015-01-20 |
Methodology
Annual rows come from the filer's 10-K and Q1–Q3 rows from
the matching 10-Q; Q4 is derived as full-year minus nine-month
YTD because XBRL doesn't tag Q4 as its own period.
EPS Basic and EPS Diluted
are reported directly by the filer.
FCF / Share is computed as
(Operating Cash Flow − Capital Expenditures) ÷ Diluted
Shares Outstanding. When SEC companyfacts omits the
direct diluted-share concept for an older period, we
imply it from NetIncomeLoss ÷ EarningsPerShareDiluted.
For financial filers whose operating cash flow includes
customer-fund activity (e.g. Mercado Pago deposits),
FCF may materially exceed net income because the fintech
float is recorded inside OCF under US GAAP.
Per-share values are split-adjusted
to the current share count (4 split
s since
2010).
For the exact XBRL concepts and formulas, see the methodology reference for EPS, FCF per share, the Q4 derivation, and split adjustment.
CNBX CIK 0001343009 Source: EDGAR filings · all facts